Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Adherence Advocates Target Coming Medicare “Doc Fix” Bill With Policy Recommendations

This article was originally published in The Pink Sheet Daily

Executive Summary

Council for Affordable Health Coverage is lobbying for policies around medication synchronization and better use of health IT, with an eye on using CBO’s scoring of savings from medication use to help pay for reforming Medicare’s physician payment updating method in upcoming legislation.

You may also be interested in...



CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs

In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.

A Personal Touch Can Help Medication Adherence, Mass General Finds

As themes of patient-centered outcomes and personalized medicine become more common in drug development, the concepts also are playing out in the medication adherence space, as shown in a program at Massachusetts General Hospital.

CMS Adopts Trial-Size Prescriptions For Part D, Delays Implementation

CMS mandates that Part D plans offer prescriptions filled for less than a 30-day period at a daily cost-sharing rate, with a few stated exceptions, but delays implementation until the 2014 plan year.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS074951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel